Kidswell Bio Corporation
4584.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.94B
Close$
Share Statistics
| Market cap | $7.94 Billion |
|---|---|
| Enterprise Value | $8.29 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.48 |
| Beta | 1.12 |
| Outstanding Shares | 49,627,967 |
Return
| Return on Equity | -20.31% |
|---|---|
| Return on Assets | -6.09% |
| Return on Invested Capital | -5.48% |
Valuation & Multiples
| P/E Ratio | -21.05 |
|---|---|
| PEG | -81.12 |
| Price to Sales | 1.3 |
| Price to Book Ratio | 4.32 |
| Enterprise Value to Revenue | 1.35 |
| Enterprise Value to EBIT | -38.14 |
| Enterprise Value to Net Income | -23 |
| Total Debt to Enterprise | 0.43 |
| Debt to Equity | 1.95 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$1.27 B
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$1.40 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Kidswell Bio Corporation
32 employees
CEO: Shinya Kurebayashi Kidswell Bio Corporation, headquartered in Tokyo, Japan, specializes in the development of pharmaceutical treatments for rare and complex diseases. The company, which was founded in 2001 and operated as Gene Techno Science Co.,Ltd. until...